Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate

Gen Hosp Psychiatry. 2006 May-Jun;28(3):230-3. doi: 10.1016/j.genhosppsych.2006.03.003.

Abstract

Delirium, depression and other psychiatric difficulties are commonly encountered by posttransplantation patients, and antipsychotic medicines are frequently used to treat these difficulties. This article reviews previous research data concerning the immunological effects of these medicines, with particular focus on the consequences of prolactin elevation. Unproven but of concern is that these effects may influence graft fate. Older antipsychotic medicines such as haloperidol and chlorpromazine have a high likelihood of elevating prolactin. Prolactin is an immunologically active molecule generally promoting bone marrow function. This may be of benefit post-stem-cell transplant, helping engraftment, but could further rejection of solid-organ transplants. Elevated prolactin is implicated in the facilitation of graft-versus-host disease. Aripiprazole is the antipsychotic medicine least likely to increase prolactin (and may actually decrease prolactin); risperidone, the most likely to increase prolactin. Olanzapine, quetiapine and ziprazadone are antipsychotic medicines with a lower likelihood of elevating prolactin. Older ("neuroleptic") antipsychotics, such as chlorpromazine, droperidol and haloperidol, perphenazine and many others, are likely to elevate serum prolactin. Among antidepressants, most serotonin reuptake inhibitors, with the exception of sertraline, can slightly elevate prolactin. The atypical (i.e., alone in their class) antidepressants bupropion and mirtazapine are prolactin neutral. The immunological consequences of psychiatric medicines should be considered when treating transplant patients for delirium, depression and thought disorders; in addition, if elevation of prolactin is thought to be of immunological importance during psychiatric treatment, then it should be monitored and treated. The dopamine agonists used to treat Parkinson's disease--bromocriptine, pergolide, pramipexole, ropinerole--usually reverse antipsychotic-induced prolactin increases without compromising psychiatric effectiveness.

MeSH terms

  • Antipsychotic Agents / immunology
  • Antipsychotic Agents / therapeutic use
  • Dopamine / immunology
  • Dopamine / therapeutic use
  • Graft Rejection*
  • Humans
  • Prolactin / blood
  • Prolactin / drug effects*
  • Prolactin / immunology
  • Selective Serotonin Reuptake Inhibitors / immunology
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Transplantation / psychology*
  • Transplantation Immunology
  • United States

Substances

  • Antipsychotic Agents
  • Serotonin Uptake Inhibitors
  • Prolactin
  • Dopamine